Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study ResultsHeinz Gisslinger, Christoph Klade, Margarete Stampfl‐Mattersberger et al.|Blood|2018Cited by 18
Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera StudyHeinz Gisslinger, Richard Greil, Veronika Buxhofer‐Ausch et al.|Blood|2013Cited by 9
AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)Heinz Gisslinger, Josef Thaler, Róbert Královics et al.|Blood|2012Cited by 5
Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II StudyHeinz Gisslinger, Richard Greil, Veronika Buxhofer‐Ausch et al.|Blood|2014Cited by 0